Clinical Trial: The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational
Official Title: The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy
Brief Summary: The purpose of this study is to gain further insights into the molecular pathogenesis of Fuchs' endothelial corneal dystrophy (FECD), to identify targets for potential specific drug therapy.
Detailed Summary:
Sponsor: Universitaire Ziekenhuizen Leuven
Current Primary Outcome:
- cytokine levels [ Time Frame: at time of prelevation (once, no intervention) ]dosage of cytokine levels in aqueous humour (exploratory, non-interventional study)
- gene expression levels [ Time Frame: at time of prelevation (once, no intervention) ]microarray expression analysis, reverse transcriptase - quantitative polymerase chain reaction (RT-qPCR), RNA-sequencing (exploratory, non-interventional study)
- protein content [ Time Frame: at time of prelevation (once, no intervention) ]immunohistochemistry and immunofluorescence
Original Primary Outcome:
- cytokine levels [ Time Frame: "Day 1": at the moment of therapeutic DSAEK (for FECD patients) or at the moment of therapeutic cataract surgery (for normal controls) (during period 2014-2016) ]dosage of cytokine level in aqueous humour
- threefold significantly over- or underexpressed genes [ Time Frame: "Day 1": at the moment of therapeutic DSAEK (for FECD patients) or in residual material of donor corneas after therapeutic use (normal control) (during period 2012-2014) ]
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Universitaire Ziekenhuizen Leuven
Dates:
Date Received: January 30, 2013
Date Started: October 2012
Date Completion: September 2017
Last Updated: May 30, 2016
Last Verified: December 2015